IICT, LAXAI LifeSciences collaborate for key pharma intermediates
The collaboration will primarily focus on umifenovir, remdesivir and a key intermediate of hydroxychloroquine
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.